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We thank Dr. La Mura for commenting on our meta-analysis con-
cerning the impact of insulin resistance (IR) on sustained virolog-
ical response (SVR) in HCV patients treated with pegylated
interferon and ribavirin [1].
We agree that other predictive factors possibly inﬂuencing
SVR rates, such as extensive ﬁbrosis, age, level of viremia, IL28B
polymorphisms, BMI and steatosis [2–4], were not taken into
account. Only a meta-analysis of individual data (frequently
unfeasible) would be able to address this issue. Despite this, it
is likely that IR itself contributes to a reduction in the likelihood
of viral eradication, given the magnitude of the reduction in SVR
rates in patients with IR (20%), its impact regardless of genotype
and absence of heterogeneity.
We also agree that overexpression of suppressors of cytokine
signaling (SOCS-3) induced by HCV may be one mechanism
explaining the non-response to antiviral therapy. The data that
Dr. La Mura presented provide additional arguments supporting
this explanation.
Finally, we agree that, ideally, a dose effect of IR on SVR rates
should be explored. However, such an approach is difﬁcult in that
it assumes that an accurate easy-to-use tool for assessing the sever-
ity of IR is available. Several limitations involved in measuring IR
using the HOMA-IR index have recently been pointed out [5], and
thus it is not certain that the HOMA-IR index is the ideal tool. In
addition, other potential confounding factors again need to be con-
sidered, since the magnitude of the impact of IR on SVR may differ
according to age, ﬁbrosis, etc. Finally, the distinction between
patients with metabolically-related IR and those with HCV-related
IR is crucial, since their respective impacts on SVR ratesmay be dif-
ferent. Therefore, up to now, and despite the limitations discussed
above, the HOMA-IR index measured prior to antiviral therapy
offers an easy way of identifying insulin-resistant patients who
have lower probability of SVR following pegylated bitherapy.
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manuscript.IBD is associated with an increase in carcinoma in PSC irrespective
of the presence of dominant bile duct stenosisTo the Editor:
We have read with great interest the paper by Rudolph et al.
[1]. The authors have prospectively studied a large cohort of
Primary Sclerosing Cholangitis (PSC) patients for up to two dec-
ades and identiﬁed that only patients with a dominant biliary
stenosis with additional IBD had an increased rate in both bil-
iary and colorectal carcinomas (CRC) compared to patients with
no dominant stenosis or patients with a dominant stenosis
without concomitant IBD. Their ﬁndings suggest that the occur-Journal of Hepatology 2rence of additional IBD in PSC patients has a carcinogenic
potential and also results in reduced survival free of liver
transplantation. The authors recommend that these patients
should be carefully screened for bile duct, gallbladder and colo-
rectal carcinomas. We would here like to present our data on
an equally large cohort of PSC patients, with a similar follow-
up, which does not substantiate their ﬁndings.
Two hundred and forty-one PSC patients (161 men, median
age of diagnosis 34 years) with an established diagnosis of PSC,012 vol. 57 j 467–477 473
